Production of no-carrier-added Lu for radioimmunotherapy
放射免疫療法のための無担体Luの製造法の開発
渡辺 智; 橋本 和幸; 渡邉 茂樹; 飯田 靖彦*; 花岡 宏史*; 遠藤 啓吾*; 石岡 典子
Watanabe, Satoshi; Hashimoto, Kazuyuki; Watanabe, Shigeki; Iida, Yasuhiko*; Hanaoka, Hirofumi*; Endo, Keigo*; Ishioka, Noriko
Lutetium-177 is considered to have potential for application in radioimmunotherapy, because it emits -particles (E=498 keV) suitable to penetrate small tumors and its physical half-life of 6.734 days is long enough for Lu-labeled antibodies to accumulate to tumor sites. In addition, real time imaging of biodistribution can be done by using the Lu, because the energy of -rays (113 keV and 208 keV) emitted from Lu is particularly suitable for imaging by single photon emission computed tomography. We can produce Lu by the Lu (n,) Lu process and the Yb(n,) Yb (T=1.911 h)Lu process. In the field of radioimmunotherapy using labeled monoclonal antibodies, to enhance the effect of therapy, no-carrier-added (nca) Lu produced in the Yb(n,) Yb (T=1.911 h) Lu process with high specific radioactivity are required. Therefore, in the present paper, production of highly-purified nca Lu from macroscopic amounts of the ytterbium target is developed.